Amneal Pharmaceuticals Inc. has announced positive interim results from its ongoing Phase 4 ELEVATE-PD study evaluating CREXONT® for Parkinson's disease. The interim data, presented at the Parkinson's Study Group Annual Meeting, indicate that patients switching to CREXONT experienced substantial increases in daily "Good On" time and reductions in "Off" time compared to other oral carbidopa/levodopa therapies. The study reported an increase of up to 3.13 hours in "Good On" time and a reduction of up to 2.83 hours in "Off" time among the first 55 patients over a six-week analysis period. Longer-term outcomes and patient-reported results are expected to be presented in 2026 as part of the ongoing ELEVATE-PD program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597312-en) on December 05, 2025, and is solely responsible for the information contained therein.